Sign in
BIOA Stock Price, Chart, Stats & News
BioAge Labs, Inc.
Save
591.10M
Market cap
–
Current P/E
–
Forward P/E
BIOA chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 99.23% |
Operating margin | -1031.46% |
Pretax margin | -896.11% |
Net margin | -896.11% |
Effective tax rate | – |
ROA | -27.33% |
ROE | -27.86% |
D/E | 0.02x |
Interest coverage ratio | -133.11x |
BIOA valuation
P/E | – |
P/S | 64.60x |
P/B | 2.13x |
P/CF | -7.11x |
P/FCF | -7.06x |
P/OCF | -7.11x |
PEG | -0.20x |
EV multiple | -9.28x |
About
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging. Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults.
Similar securities
Based on sector and market capitalization
Report issue